Accueil   Diary - News   All news Adocia and Lilly report positive results

Adocia and Lilly report positive results

Adocia and Lilly report positive results of a pilot bioequivalence study comparing BioChaperone Lispro U200 to BioChaperone Lispro U100

 

 

Adocia and Eli Lilly and Company announced the successful completion of a preliminary Phase 1 clinical trial evaluating BioChaperone Lispro U200, a concentrated formulation of BioChaperone Lispro, the ultra-rapid formulation of insulin lispro licensed to Lilly. This completed pilot study aimed to determine the potential for bioequivalence of BioChaperone Lispro U200 to BioChaperone Lispro U100 in healthy volunteers.

 

 

Read the press release

 

 

 

 

By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to dpo@lyonbiopole.com. More details are available by clicking here I agree